Navitoclax-piperazine
Navitoclax-piperazine, also known as ABT-263-piperazine, is a potent and selective BCL-XL inhibitor. It is widely used in oncology research, demonstrating efficacy in inducing apoptosis in cellular assays and showing activity in preclinical in vivo models of hematologic cancers.
Product Specifications
CAS Number
2143096-93-7
Product Name Alternative
ABT-263-piperazine, B-cell, Bcl-xL, Bcl-2 Family, Ligands for Target Protein for PROTAC, LigandsforTargetProteinforPROTAC, ligase, inhibit, lymphoma, Navitoclax piperazine, Navitoclaxpiperazine, Navitoclax-piperazine, Inhibitor, Target Protein-binding Moiety, VHL, ubiquitin
Field of Research
Cell Biology, Pharmacology & Drug Discovery
Purity
99.11% (May vary between batches)
Solubility
10% DMSO+90% Corn Oil:3.3 mg/mL (3.39 mM) ; DMSO:250 mg/mL (256.77 mM)
Smiles
CC1 (C) CCC (=C (CN2CCN (CC2) c2ccc (cc2) C (=O) NS (=O) (=O) c2ccc (N[C@H] (CCN3CCNCC3) CSc3ccccc3) c (c2) S (=O) (=O) C (F) (F) F) C1) c1ccc (Cl) cc1
Molecular Formula
C47H56ClF3N6O5S3
Molecular Weight
973.63
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
